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Cancer and Alzheimer’s disease (AD) are commonly
found among elderly patients. Chronic inﬂammation is the
characteristic of both diseases. Amyloid-b peptide is the
main inducer of inﬂammation in AD. Moreover, chronic
inﬂammation promotes cancer, suggesting that AD
patients may be more prone to develop cancer than non-
demented people. To test this hypothesis, we injected the
carcinogen 20-methylcholanthrene in the brain of trans-
genic mice overexpressing the mutant forms of amyloid
precursor protein (APP) and presenilin 1 (PS1), as a
model of AD, and their wild-type (WT) littermates.
Mutant mice developed tumors faster and with higher
incidence than their WT counterparts. Expression of the
inﬂammatory markers interleukin (IL)-1a, IL-1b, IL-6,
IP-10 and tumor necrosis factor-a (TNF-a) was measured
in AD and WT mice of 3 and 12 months of age that had
not been exposed to the carcinogen. These cytokines were
elevated in older AD mice, indicating the existence of a
highly inﬂammatory milieu in these animals. We also
found elevated expression of a mutated form of p53 in
older AD mice, suggesting an alternative mechanism for
the predisposition of AD brains to develop brain tumors.
Clinical studies reporting comorbidity of AD and brain
cancer are needed to understand whether our observations
hold true for humans.
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Introduction
Both cancer and Alzheimer’s disease (AD) are common
clinical ﬁndings in elderly people. The probability of
developing either one of them increases with age
(Anisimov, 2007), although for cancer this probability
may experience a slight reduction after the eighth decade
(Driver et al., 2008). Chronic inﬂammation is a common
trait in the pathogenesis of both diseases (Leonard,
2007; Paugh et al. 2009). Nowadays, it is widely
accepted that aging is accompanied by a low-grade
chronic upregulation of proinﬂammatory responses and,
even if in many individuals this inﬂammation remains
subclinical, in some people it may promote a number of
age-associated diseases such as cancer or AD (Giunta
et al., 2008).
More than 20 epidemiologic surveys have consistently
showed that common non-steroidal anti-inﬂammatory
drugs may protect against the development of AD
(Rogers, 2008) and, although mono-targeted therapies
have proven so far ineffective in preventing AD, new
agents that block several cellular pathways simulta-
neously are being analyzed (Harikumar and Aggarwal,
2008). It seems that amyloid-b peptide, which is derived
from the longer amyloid precursor protein (APP), is the
main stimulator of the inﬂammatory response found in
the brain of AD patients (Sastre et al., 2008), resulting
in the presence of activated microglia and astrocytes
around neuritic plaques (Rodrigo et al., 2004) and
increased levels of inﬂammatory mediators (Hoozemans
et al., 2008). Some current hypotheses suggest that even
peripheral chronic infections, such as periodontal
episodes, may affect the onset and progression of AD
(Kamer et al., 2008).
In contrast, the link between inﬂammation and cancer
is widely accepted (Coussens and Werb, 2002; Hussain
et al., 2003). During tumor progression a proinﬂamma-
tory crosstalk gets established among the different
components of the tumor and the stroma (Mbeunkui
and Johann, 2009). Cancer cells and neighboring
epithelial cells activate inﬂammatory pathways such as
the arachidonic acid-cyclooxygenase cascade that
secrete prostaglandins to the extracellular milieu. These
molecules exert an effect as chemoattractants for
macrophages and other inﬁltrating cells that would
secrete proinﬂammatory interleukins, especially inter-
leukin-6 (IL-6), in the proximity of the tumor. These
interleukins promote tumor cell proliferation and clonal
expansion (Hong et al., 2000), thus establishing a
difﬁcult-to-break positive feedback loop that may even
stimulate metastasis production (Kim et al., 2009).
In addition, several studies have found elevated
expression of key oncogenes, such as p53 or epidermal
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growth factor receptor, and loss of tumor suppressor
genes, such as PTEN (phosphatase and tensin homolog
deleted on chromosome 10), in AD patients when
compared with age-matched controls (Grifﬁn et al.,
2005; Lanni et al., 2008; Uberti et al., 2008; Di et al., 2009).
Given this scenario, we would suspect that a high
degree of comorbidity must exist for these two diseases.
Clinical data on this issue are scarce and somehow
contradictory. In most studies, cancer seems to be a
prevalent comorbidity for patients with AD, and for
males in particular (Gambassi et al., 1999; Gasper et al.,
2005), although speciﬁc proportions vary from 8%
(Formiga et al., 2007, 2008) to almost 23% in patients
with reported exposure to carcinogens (Yamada et al.,
1999). Other studies ﬁnd that the risk of developing
cancer, in organs distant from the central nervous
system, is lower among AD patients than in non-
demented patients (Beard et al., 1996; Roe et al., 2005).
In a post-mortem histopathological study, 42% of
patients diagnosed with a brain tumor also had
unreported signs of AD (Nelson, 2002), indicating that
the coexistence of both diseases may be grossly under-
reported in the clinical literature.
To analyze whether there is a causal connection
between AD and brain cancer, we designed a study in
which genetically engineered mice that mimic AD and
their wild-type (WT) counterparts were exposed to a
carcinogen in the brain and the time until they
developed brain tumors was recorded. Mice suffering
from AD symptoms developed tumors much earlier and
with higher incidence than control mice, indicating that
AD may be a predisposing condition for brain cancer.
Results
Tumor generation in the brain of mutant and WT animals
Mice carrying the double transgene for mutated APP
and presenilin 1 (PS1) and their WT littermates were
exposed to equal intracranial amounts of the carcinogen
20-methylcholanthrene. The ﬁrst symptoms of the
presence of a brain tumor were lethargy, insecure gait
and hair erection. In some cases, the tumor grew
through the skull burr hole and under the scalp. The
ﬁnal phase of tumor progression was exponential and
mice had to be killed at o48 h after the onset of
symptoms for welfare reasons. Histologically, tumors
were malignant gliomas (either astrocytomas or glio-
blastomas) as indicated by their invasiveness, the
presence of nuclear atypia and speciﬁc histogenetic
markers, including glial ﬁbrillary acidic protein, Sox9
and vimentin (Figure 1). A case of sarcoma was detected
surrounding the carcinogen that was incorrectly located
in contact with the meninges in a double-mutant mouse
(data not shown). This animal was excluded from the
analysis. No histological differences were found between
tumors produced in mutant or WT mice. Interestingly,
double-mutant mice began to develop brain tumors
much earlier than their WT counterparts and with
higher incidence (88% for the mutants vs 54% in the
WT). A Kaplan–Meier tumor-free survival curve shows
the striking differences between genotypes (Po0.001)
with a mean tumor-free survival of 275 days for the WT
animals and of only 80 days for the double transgenic
mice (Figure 2).
Quantiﬁcation of inﬂammatory mediators
Numerous studies point out the presence of inﬂamma-
tory mediators in the AD brain (Sastre et al., 2008;
Salminen et al., 2009). To analyze whether this is also
true in our mouse model and whether these inﬂamma-
tory markers increase with age and disease progression,
we performed quantitative real-time PCR for several
inﬂammatory mediators (Figure 3). Expression of IL-
1a, IL-1b and IP-10 increased in older mutant mice
when compared with younger animals (Figures 3a, b
and d). IL-6 and tumor necrosis factor-a (TNF-a) had a
similar expression pattern, in which older mutant mice
had signiﬁcantly higher expression than younger mice of
the same genotype and than WT animals of the same age
(Figures 3c and e). These data indicate that mice
suffering from AD symptoms present a brain paren-
chyma that is rich in inﬂammatory cytokines.
Oncogene expression quantiﬁcation
Accumulation of altered forms of p53 has been reported
in AD patients (Uberti et al., 2008). In our animal model
we have observed a signiﬁcant increase in the expression
of mutated p53 in older AD animals when compared
with younger mutants and with WT counterparts of the
same age (Figure 3f), thus conﬁrming the previously
reported accumulation of these p53 variants.
Discussion
In this study we have shown that mice carrying
mutations in the AD-speciﬁc genes, APP and PS1, are
much more sensitive to the carcinogen 20-methylchol-
anthrene than their WT counterparts. In addition, aged
AD mice that had not been exposed to carcinogens
presented higher levels of the proinﬂammatory media-
tors IL-1a, IL-1b, IL-6, IP-10 and TNF-a than younger
or WT mice. The tumor marker p53 was also elevated
in untreated AD mice when compared with their WT
littermates.
Tumors developed in our WT mice with a timeframe
(mean¼ 275 days) perfectly in agreement with Zimmer-
man’s initial manuscript (mean¼ 279 days for gliomas;
Zimmerman and Arnold, 1941). In our experimental set,
we obtained a 54% tumor incidence rate among the WT
animals in comparison with 47% observed in Zimmer-
man’s paper (Zimmerman and Arnold, 1941). This small
discrepancy may be due to the use of different mouse
strains. On the other hand, double transgenic mice
generated tumors faster (mean¼ 80 days) and had a
higher tumor incidence rate (88%), indicating that AD
may predispose to develop brain tumors in the presence
of a carcinogen.
The concept of ‘seed and soil’, initially coined by
Stephen Paget, postulates the important role that the
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microenvironment has in the development of primary
and metastatic tumor growth, and proinﬂammatory
stimuli have primary roles in the conditioning of the
tumor niche (Ribatti et al., 2006; Psaila and Lyden,
2009). Inﬂammation has been shown to be critical for
promoting apoptosis resistance, proliferation, invasion,
metastasis and secretion of proangiogenic and immu-
nosuppressive factors in tumors of different origins,
including lung (Peebles et al., 2007), prostate (Stock
et al., 2008), breast (Hu and Polyak, 2008), stomach
(Correa and Houghton, 2007), pancreas (Chu et al.,
2007), gut (Quante and Wang, 2008) and, of course, the
brain (Murat et al., 2009; Paugh et al., 2009). Thus, it is
easy to imagine how the brain parenchyma of an AD
patient, which is rich in proinﬂammatory mediators,
would be a good environment for the development and
progression of brain tumors.
To show that the brain of AD mice had higher levels
of proinﬂammatory markers, the expression of several
interleukins was analyzed using real-time PCR in the
brain of untreated mutant and WT mice. IL-1a, IL-1b,
IL-6, TNF-a and IP-10 were all upregulated in older AD
mice, suggesting that their brain parenchyma was
specially prepared to host a developing tumor. IL-1 is
a cytokine that promotes tumorigenesis, tumor inva-
siveness, metastasis and tumor–host interactions (Apte
et al., 2006). IL-6 is also involved in tumor progression
and it has been shown clinically that its levels correlate
negatively with patient survival (Chang et al., 2005).
TNF-a induces tumor cell death but it can also exert an
effect as a mitogen and migration agent (Chicoine and
Silbergeld, 1997), representing a dual component of the
inﬂammatory cascade that can either drive or repress
tumor growth depending on the environmental context.
IP-10, also known as CXCL10, is an antiangiogenic
Figure 1 Histological sections of the brain of double transgenic (a) and wild type (WT) (b) mice, which had been injected with the
carcinogen and developed tumors, stained with Congo red and counterstained with hematoxylin. Neuritic plaques containing
b-amyloid stain positive for the Congo red dye in the APP-PS1 mice (arrows in a) but they are absent in the parenchyma of the WT
animals (b). Tumors and their periphery contain a large number of blood vessels (asterisks in a, b). Immunohistochemical staining for
glial ﬁbrillary acidic protein (GFAP) (c), Sox9 (d) and vimentin (e) in a tumor that developed in a mutant mouse. Bar¼ 200mm for
a and b, and 20mm for c–e.
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Figure 2 Kaplan–Meier tumor-free survival curves comparing the
double mutant mice (APP-PS1) (n¼ 9) with their wild-type (WT)
littermates (n¼ 10) after carcinogen exposure at day 0. Little
crosses represent censored data. Analysis of the curves shows a
50% tumor-free survival for APP-PS1 animals of 80 days whereas
for WT mice it goes to 275 days. An important statistically
signiﬁcant difference was observed between genotypes (Po0.001).
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protein whose expression is regulated by IL-1b, inter-
feron-g and TNF-a (Yeruva et al., 2008); thus, in view
of the overexpression of these markers in the AD brains,
the activation of this downstream protein is expected.
Although IP-10 can be considered an ‘anti-tumoral’
cytokine, its upregulation in AD mice shows that there is
a marked elevation of all members of the inﬂammatory
cascade. In summary, all these data suggest that the
cerebral parenchyma of mice suffering from AD symp-
toms contains a dangerous cocktail of proinﬂammatory
mediators that would promote tumor growth once the
initial malignant mutations occur. An important experi-
ment to be performed in the future will imply the chronic
treatment of AD mice with anti-inﬂammatory drugs to
analyze whether there is a delay in brain cancer onset.
But inﬂammation is not restricted to AD among
neurodegenerative disorders and other common diseases
of the CNS (Steinman, 2008). On the contrary,
inﬂammatory mediators are commonly produced in
Parkinson’s disease (Tansey et al., 2008), multiple
sclerosis (Sanders and De, 2007), schizophrenia (Saetre
et al., 2007) or AIDS dementia complex (Vesce et al.,
2007), to cite just some examples. Therefore, we could
expect that the brain microenvironment in all these
conditions will be especially conducive for cancer
growth. Clinical studies correlating inﬂammatory dis-
eases of the brain and tumor development and progres-
sion are warranted.
An interesting observation is the accumulation of
mutated p53 in older AD mice. This has been previously
reported in patients (Uberti et al., 2008) and has been
shown as a link between neural stem cells and tumors of
the brain (Wang et al., 2009). The researchers of these
studies postulate that the AD brain is characterized by
high levels of reactive oxygen/nitrogen species and a
concomitant decrease in the levels of antioxidant
enzymes (Di et al., 2009). Under these conditions, the
mutant-like form of p53 becomes elevated, glutathiony-
Figure 3 Expression of inﬂammatory markers and oncogenes as revealed using quantitative real-time PCR. RNA was extracted from
the brain of double-mutant (AD) and wild-type (WT) mice at the ages of 3 and 12 months (mth.). After reverse transcription, the
complementary (c)DNAs were tested for IL-1a (a), IL-1b (b), IL-6 (c), IP-10 (d), TNF-a (e) and p53 (f). All data were normalized by
the 18S ribosomal (r)RNA value in each sample. Bars represent mean±s.d. of three independent samples. Statistically signiﬁcant
differences are indicated by asterisks. *Po0.05; **Po0.01; ***Po0.001.
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lated and suffers conformation changes in a way that
favors monomers or dimers while preventing formation
of the tetramers, which is the aggregate form needed for
effective action of p53 (Lanni et al., 2008; Di et al.,
2009). As p53 is the main guardian of the cell division
checkpoint, blocking this molecule will result in
progressive accumulation of mutational events and will
eventually lead to cancer development. Obviously, this
oncogene hypothesis is complementary rather than
mutually excluding with the involvement of inﬂamma-
tion in the onset of the brain tumors.
Clinical studies reporting the comorbidity of brain
tumors and other diseases of the central nervous system
are needed to conﬁrm whether these observations in
mouse models correlate with the human paradigm.
Materials and methods
Animals
Two transgenic mice strains, carrying the human mutated
alleles for APP (Hsiao et al., 1996) or PS1 (Duff et al., 1996),
were a generous gift from Professor Ignacio Torres (Instituto
Cajal, Madrid, Spain). Both strains were crossed to obtain
heterozygotes for both alleles, which were used as the parental
generation for the experiment. The offspring of these double
heterozygotes were genotyped and the WT and double-mutant
male littermates were chosen for carcinogen exposure. Double
mutants for APP and PS1 (APPswe/PS1-A246E) have been
shown to produce AD symptoms much earlier than either one
of the single mutants (Borchelt et al., 1997).
Carcinogen exposure
Following Zimmerman’s methodology (Zimmerman and
Arnold, 1941), 20-methylcholanthrene (MP Biomedicals,
LLC, Solon, OH, USA) pellets were deeply implanted into
the brains (right parietal subcortex) of 9-month old mice (9
double mutants and 10 WT littermates) by intracranial incision
using stereotaxic guidance. Mice were deeply anesthetized with
pentobarbital (10mg/kg) and atropine (90mg/kg) intraperito-
neally and placed in a mouse stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA). While under deep anesthe-
sia, a sagittal incision was made through the skin to expose the
skull, and a burr hole was drilled at 0.1mm anterior and
2.25mm lateral to bregma. A Hamilton syringe (Hamilton,
Reno, NV, USA) with a 27-gauge needle was inserted at the
depth of 2.7mm from brain surface to open an access to the
CP, and the crystals were inserted there with the help of thin
forceps. The burr hole was then ﬁlled with spongostan
(Ferrosan A/S, Soeborg, Denmark) and the scalp sutured.
The animals were periodically observed for signs of neurolo-
gical alterations and/or tumor growth and were killed when
these alterations compromised their comfort and quality of
life. Some brains were ﬁxed with 4% paraformaldehyde in
phosphate buffer 0.1M pH 7.4, stored in cryoprotectant (30%
sucrose in phosphate buffer) overnight and cut into 40-mm-thick
sections with the help of a cryostat. These sections were then
stained. Stains included Congo red and hematoxylin to study
morphology and the presence of neuritic plaques and immuno-
histochemistry with antibodies against glial ﬁbrillary acidic
protein (1:1000, rabbit polyclonal, DK 2600, Dako, Glostrup,
Denmark), vimentin (1:1000, rabbit polyclonal, Abcam, Cam-
bridge, MA, USA) and Sox9 (1:2000, rabbit polyclonal). The
presence of transcription factor Sox9 was screened with
antibodies that have been previously characterized (Stolt et al.,
2003) and were a generous gift from Dr Michael Wegner (Institut
fur Biochimie, Universitat Erlangen-Nuremberg, Germany).
Immunohistochemistry was performed following standard pro-
tocols (Serrano et al., 2008). Kaplan–Meier tumor-free survival
curves were plotted and statistically analyzed using SPSS
software (SPSS, Inc., Chicago, IL, USA).
All procedures were carried out in accordance with the
European Communities Council Directive (86/609/EEE) on
animal experiments and with approval from the ethical
committee of the Instituto Cajal.
Expression analysis of oncogenes and inﬂammatory mediators
Additional animals (n¼ 3 for each group) of different ages
(3 and 12 months) and genotypes that had not been exposed
to the carcinogen were used to obtain mRNA. After deep
anesthesia, the brain was rapidly dissected out and frozen in
liquid N2. The RNA was extracted with Trizol (Invitrogen,
Carlsbad, CA, USA) and reverse transcribed using SuperScript
reverse transcriptase (Invitrogen). Real-time PCR was
performed using the Chromo4 (MJ Research, Hercules,
CA, USA) thermocycler and software. Ampliﬁcation was
performed in a ﬁnal volume of 25 ml, containing 2 ml
complementary DNA (diluted 1:10), 2ml of primer mixture
(at 10 nM) and 12.5ml of 2 SYBR Green Master Mix
(Applied Biosystems, Foster City, CA, USA). Values were
determined by interpolation within a standard curve. At the
Table 1 Primers used for quantitative real-time PCR
Gene Primer sequence Annealing
temperature
IL-1a Sense: 50-GCACCTTACACCTACCAGAGT-30
Antisense: 50-AAACTTCTGCCTGACGAGCTT-30
60 1C
IL-1b Sense: 50-GCAACTGTTCCTGAACTCAACT-30 60 1C
Antisense: 50-ATCTTTTGGGGTCCGTCAACT-30
IL-6 Sense: 50-GAAACCGCTATGAAGTTCCTCTCTG-30 60 1C
Antisense: 50-TGTTGGGAGTGGTATCCTCTGTGA-30
IP-10 Sense: 50-CAGTGAGAATGAGGGCCATAGG-30 60 1C
Antisense: 50-CGGATTCAGACATCTCTGCTCAT-30
TNF-a Sense: 50-CCCTCACACTCAGATCATCTTCT-30 60 1C
Antisense: 50-GCTACGACGTGGGCTACAG-30
p53 Sense: GTCACAGCACATGACGGAGG-30 60 1C
Antisense: 50-TCTTCCAGATGCTCGGGATAC-30
18S rRNA Sense: 50-ATGCTCTTAGCTGAGTGTCCCG-30 60 1C
Antisense: 50-ATTCCTAGCTGCGGTATCCAGG-30
Abbreviations: IL, interleukin; rRNA, ribosomal RNA; TNF-a, tumor necrosis factor-a.
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end of the PCR, a melting curve was generated to ascertain
amplicon quality. All gene expression values were normalized
according to the 18S ribosomal RNA concentration of each
sample. The primers are shown in Table 1.
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